Generated by Apex Intelligence. Verify key information against the sources. For information and education, not personalized investment advice. See full disclaimer

Worth notingMarket eventTue, Oct 201 min read

GSK wins US FDA approval for hepatitis B treatment Hibsago

A potential alternative to indefinite treatment opens a sales opportunity for GSK and changes competition for existing hepatitis B medicines.

The US Food and Drug Administration has approved GSK's Hibsago, also called bepirovirsen, to treat chronic hepatitis B—a persistent infection with the hepatitis B virus. Ionis Pharmaceuticals is GSK's partner on the drug.^[1]^[2]

The treatment's key distinction is the potential to let patients stop therapy that otherwise continues long term. That is a possibility, not a promise that every patient can stop treatment or is cured.^[1]

Approval allows GSK to sell Hibsago in the United States. For doctors and patients, the possibility of eventually stopping treatment is a reason to consider the new option; prescribing it would generate revenue for GSK and create competition for existing hepatitis B therapies. Approval alone, however, does not establish prescribing uptake or sales volume.^[1]

Jefferies said the approval supported its £2.2 billion sales forecast for the drug. That signals the commercial potential the analyst sees, but remains a forecast rather than realized revenue.^[3]

Impact

Back to the market Watch with Lumi

Hepatitis B medicinesOpportunity
GSK gains a product it can sell in the US, with the prospect of stopping long-term treatment giving doctors a different option. Existing hepatitis B drugmakers face a new competitor, but the impact depends on Hibsago's actual uptake; this is not evidence of a sales increase across the industry.^[1]^[2]